Heliyon · 2023
Fibrinogen-to-albumin ratios are related to mortality in patients with secondary malignant neoplasm of bone and bone marrow.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhong Jinsha
Аннотация
BACKGROUND: Systemic inflammation has long been considered to be one of the mechanisms in the development and progression of secondary malignant neoplasm of bone and bone marrow (BM). Fibrinogen-to-albumin ratio (FAR) has been demonstrated to be vital to the poor prognosis of lots of disease such as tumor and coronary heart disease. This study aimed to determine whether FAR could be used as an independent risk prognostic factor in patients with BM.
METHODS: Firstly, the baseline data of patients with BM, who met our inclusion/exclusion criteria, were extracted and analyzed from MIMIC-III database. The association between FAR and endpoints was analyzed using a Cox proportional hazards regression model and a propensity score matched analysis.
RESULTS: The univariate analysis revealed that for the 30-day mortality, the HR (95% CI) in the FAR ≥99.5group was 1.47 (1.15,1.91). After adjusting various factors, FAR ≥99.5 was found to be an independent significant risk factor for death in patients with BM (HR = 1.11, 95% CI: 1.01-1.42). Similarly, for the one-year mortality, HR (95% CI) in the FAR ≥99.5 group was 1.51 (1.11, 2.06).
CONCLUSION: It has been found that FAR provides independent prognostic information for mortality among patients with secondary malignant neoplasms of the bone and bone marrow.
METHODS: Firstly, the baseline data of patients with BM, who met our inclusion/exclusion criteria, were extracted and analyzed from MIMIC-III database. The association between FAR and endpoints was analyzed using a Cox proportional hazards regression model and a propensity score matched analysis.
RESULTS: The univariate analysis revealed that for the 30-day mortality, the HR (95% CI) in the FAR ≥99.5group was 1.47 (1.15,1.91). After adjusting various factors, FAR ≥99.5 was found to be an independent significant risk factor for death in patients with BM (HR = 1.11, 95% CI: 1.01-1.42). Similarly, for the one-year mortality, HR (95% CI) in the FAR ≥99.5 group was 1.51 (1.11, 2.06).
CONCLUSION: It has been found that FAR provides independent prognostic information for mortality among patients with secondary malignant neoplasms of the bone and bone marrow.